NCT04841421 is a EARLY_PHASE1 clinical trial of 89Zr-CD147 in Solid Tumor, sponsored by Sinotau Pharmaceutical Group.

Who is sponsoring NCT04841421?

NCT04841421 is sponsored by Sinotau Pharmaceutical Group.

What drugs are being tested in NCT04841421?

Interventions in NCT04841421: 89Zr-CD147.

What condition does NCT04841421 study?

NCT04841421 studies Solid Tumor.

Is NCT04841421 still recruiting?

NCT04841421 is currently status unknown. Last updated 12 April 2021.

Last reviewed 2021-04-12 · How we verify

NCT04841421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Status unknown EARLY_PHASE1 Last updated 12 April 2021

What this trial tests

EARLY_PHASE1 trial testing 89Zr-CD147 in Solid Tumor in 30 participants. Status unknown.

Timeline

1 May 2021

Primary endpoint
1 March 2023

1 March 2024

Quick facts

Lead sponsor	Sinotau Pharmaceutical Group
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	1 May 2021
Primary completion	1 March 2023
Estimated completion	1 March 2024

Drugs / interventions tested

89Zr-CD147 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Sinotau Pharmaceutical Group — full company profile →

Who can join

Adults 18 to 70, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to observe the distribution of 89Zr-CD147 and radiation dosimetry characteristics in patients with solid tumors. The secondary objective is to observe the pharmacokinetic characteristics of 89Zr-CD147 in patients with solid tumors. This study is a single-center, open-lable study, including 89Zr-CD147 1mCi±10%，89Zr-CD147 3mCi±10% and 89Zr-CD147 5mCi±10% dose group. The trial is expected to last for 2 years from the first patient signing the consent form to the end of the trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.
Badier L, Quelven I. · · 2024 · cited 11× · PMID 39065579 · DOI 10.3390/pharmaceutics16070882
CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.
Yang XM, Bian H, Chen ZN. · · 2026 · cited 1× · PMID 41454696 · DOI 10.1002/advs.202518884

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Sinotau Pharmaceutical Group trials

Trials by the same sponsor.

NCT07149831 — A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics o · Phase 1 · recruiting
NCT07115277 — Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cance · NA · recruiting
NCT07187895 — Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis · Phase 2 · terminated
NCT07115238 — Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD · Phase 3 · recruiting
NCT06398444 — A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04841421 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinotau Pharmaceutical Group
Last refreshed: 12 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04841421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing